Clinical Cancer Research, Vol 3, Issue 8 1419-1425, Copyright © 1997 by American Association for Cancer Research

ARTICLES

Multidrug resistance-associated protein in acute myeloid leukemia: No impact on treatment outcome

M Filipits, RW Suchomel, S Zochbauer, R Brunner, K Lechner and R Pirker
Divisions of Oncology and Hematology, Department of Internal Medicine I, University of Vienna Medical School, Wahringer Gurtel 18-20, A-1090 Vienna, Austria.

Drug resistance remains a major problem in the treatment of patients with acute myeloid leukemia (AML). Expression of the MDR1 gene in leukemic cells was shown previously to be associated with worse clinical outcome of the patients. The multidrug resistance-associated protein (MRP) has been shown recently to be another protein causing the multidrug resistance phenotype in cell lines, but its impact on clinical outcome in patients with AML remains to be proven. To determine the clinical significance of MRP in patients with de novo AML, we have studied the MRP expression in leukemic cells and its association with both response to induction chemotherapy and survival of the patients. MRP gene expression was determined by immuno-cytochemistry (n = 80) by means of the monoclonal antibodies QCRL-1 and QCRL-3. MRP expression was low, intermediate, and high in 19, 55, and 26% of the patients, respectively. High MRP expression was independent of age and sex of the patients, WBC count, and percentage of blasts. However, high MRP expression was more frequent in the FAB M5 subtype as compared to the other subtypes. MRP expression had no impact on clinical outcome. The complete remission rates were 65, 68, and 63% for patients with low, intermediate, and high expression, respectively. Overall survival was also independent of MRP expression. In contrast, patients with P-glycoprotein-positive AML had lower complete remission rates and shorter durations of survival. These data indicate that MRP is expressed in patients with de novo AML but, in contrast to P-glycoprotein, does not predict for outcome of induction chemotherapy or survival.

This article has been cited by other articles:

				J. E. Kolitz, S. L. George, R. K. Dodge, D. D. Hurd, B. L. Powell, S. L. Allen, E. Velez-Garcia, J. O. Moore, T. C. Shea, E. Hoke, et al. Dose Escalation Studies of Cytarabine, Daunorubicin, and Etoposide With and Without Multidrug Resistance Modulation With PSC-833 in Untreated Adults With Acute Myeloid Leukemia Younger Than 60 Years: Final Induction Results of Cancer and Leukemia Group B Study 9621 J. Clin. Oncol., November 1, 2004; 22(21): 4290 - 4301. [Abstract] [Full Text] [PDF]

				T. Nakanishi, J. E. Karp, M. Tan, L. A. Doyle, T. Peters, W. Yang, D. Wei, and D. D. Ross Quantitative Analysis of Breast Cancer Resistance Protein and Cellular Resistance to Flavopiridol in Acute Leukemia Patients Clin. Cancer Res., August 1, 2003; 9(9): 3320 - 3328. [Abstract] [Full Text] [PDF]

				D. Steinbach, J. Lengemann, A. Voigt, J. Hermann, F. Zintl, and A. Sauerbrey Response to Chemotherapy and Expression of the Genes Encoding the Multidrug Resistance-associated Proteins MRP2, MRP3, MRP4, MRP5, and SMRP in Childhood Acute Myeloid Leukemia Clin. Cancer Res., March 1, 2003; 9(3): 1083 - 1086. [Abstract] [Full Text] [PDF]

				H. Takemura, Y. Urasaki, A. Yoshida, T. Fukushima, and T. Ueda Simultaneous Treatment with 1-{beta}-D-Arabinofuranosylcytosine and Daunorubicin Induces Cross-Resistance to Both Drugs due to a Combination-specific Mechanism in HL60 Cells Cancer Res., January 1, 2001; 61(1): 172 - 177. [Abstract] [Full Text]

				M. Filipits, U. Jaeger, I. Simonitsch, C. Chizzali-Bonfadin, H. Heinzl, and R. Pirker Clinical Relevance of the Lung Resistance Protein in Diffuse Large B-Cell Lymphomas Clin. Cancer Res., September 1, 2000; 6(9): 3417 - 3423. [Abstract] [Full Text]

				D. M. van der Kolk, E. G. E. de Vries, W. L. J. van Putten, L. F. Verdonck, G. J. Ossenkoppele, G. E. G. Verhoef, and E. Vellenga P-glycoprotein and Multidrug Resistance Protein Activities in Relation to Treatment Outcome in Acute Myeloid Leukemia Clin. Cancer Res., August 1, 2000; 6(8): 3205 - 3214. [Abstract] [Full Text]

				D. M. van der Kolk, E. Vellenga, A. Y. van der Veen, L. Noordhoek, H. Timmer-Bosscha, G. J. Ossenkoppele, R. A. Raymakers, M. Muller, E. van den Berg, and E. G. E. de Vries Deletion of the multidrug resistance protein MRP1 gene in acute myeloid leukemia: the impact on MRP activity Blood, June 1, 2000; 95(11): 3514 - 3519. [Abstract] [Full Text] [PDF]

				O. Legrand, G. Simonin, A. Beauchamp-Nicoud, R. Zittoun, and J.-P. Marie Simultaneous Activity of MRP1 and Pgp Is Correlated With In Vitro Resistance to Daunorubicin and With In Vivo Resistance in Adult Acute Myeloid Leukemia Blood, August 1, 1999; 94(3): 1046 - 1056. [Abstract] [Full Text] [PDF]

				C. P. Leith, K. J. Kopecky, I-M. Chen, L. Eijdems, M. L. Slovak, T. S. McConnell, D. R. Head, J. Weick, M. R. Grever, F. R. Appelbaum, et al. Frequency and Clinical Significance of the Expression of the Multidrug Resistance Proteins MDR1/P-Glycoprotein, MRP1, and LRP in Acute Myeloid Leukemia. A Southwest Oncology Group Study Blood, August 1, 1999; 94(3): 1086 - 1099. [Abstract] [Full Text] [PDF]

				D. R. Hipfner, Q. Mao, W. Qiu, E. M. Leslie, M. Gao, R. G. Deeley, and S. P. C. Cole Monoclonal Antibodies That Inhibit the Transport Function of the 190-kDa Multidrug Resistance Protein, MRP. LOCALIZATION OF THEIR EPITOPES TO THE NUCLEOTIDE-BINDING DOMAINS OF THE PROTEIN J. Biol. Chem., May 28, 1999; 274(22): 15420 - 15426. [Abstract] [Full Text] [PDF]

				M.L. den Boer, R. Pieters, K.M. Kazemier, M.M.A. Rottier, C.M. Zwaan, G.J.L. Kaspers, G. Janka-Schaub, G. Henze, U. Creutzig, R.J. Scheper, et al. Relationship Between Major Vault Protein/Lung Resistance Protein, Multidrug Resistance-Associated Protein, P-Glycoprotein Expression, and Drug Resistance in Childhood Leukemia Blood, March 15, 1998; 91(6): 2092 - 2098. [Abstract] [Full Text] [PDF]

				M. Filipits, G. Pohl, T. Stranzl, R. W. Suchomel, R. J. Scheper, U. Jager, K. Geissler, K. Lechner, and R. Pirker Expression of the Lung Resistance Protein Predicts Poor Outcome in De Novo Acute Myeloid Leukemia Blood, March 1, 1998; 91(5): 1508 - 1513. [Abstract] [Full Text] [PDF]